Drugs / TST005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04958434 | Jun 2021 → Sep 2023 | cancer of unknown primary site | Suzhou Transcenta Therapeutics Co., Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-11-11 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting transcenta.com ↗
As of Aug 24, 2022, the first three dose cohorts have been completed and no DLT was observed. |
| 2021-10-13 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Announces CDE Acceptance of IND Application of its PD-L1/TGF-β Bi-functional Antibody TST005 transcenta.com ↗ |
| 2021-04-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005 transcenta.com ↗
Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody. |
| 2021-04-16 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting transcenta.com ↗
TST005 displayed potent activity in vitro in reversing TGF-β induced T-cell suppression. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-11 | Suzhou Transcenta Therapeutics Co., Ltd. | Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting transcenta.com ↗ |
| 2021-10-13 | Suzhou Transcenta Therapeutics Co., Ltd. | Transcenta Announces CDE Acceptance of IND Application of its PD-L1/TGF-β Bi-functional Antibody TST005 transcenta.com ↗ |
| 2021-07-15 | Suzhou Transcenta Therapeutics Co., Ltd. | Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005 transcenta.com ↗ |
| 2021-04-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005 transcenta.com ↗ |
| 2021-04-16 | Suzhou Transcenta Therapeutics Co., Ltd. | Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting transcenta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TST005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04958434 ↗ |
| Route | Intravenous | “Dosed every 3 weeks IV with TST005, starting dose is 1 mg/kg” NCT04958434 ↗ |